Key result
Device-based and biologic therapies offer promising adjunctive options for non-revascularizable refractory angina.
Why the study?
Refractory angina poses a clinical challenge in patients with obstructive CAD who remain symptomatic despite optimal medical therapy and lack revascularization options.
This review provides an updated appraisal of device-based and biologic therapies for managing refractory angina in patients ineligible for revascularization.
May inform therapy selection for refractory angina; leaves open need for randomized trials before practice change.
Refractory angina (RA) represents a growing challenge in clinical cardiology, particularly in patients with obstructive coronary artery disease (CAD) who remain symptomatic despite optimal medical therapy and who are not candidates for revascularization. Advances in both device-based and biologic therapies have introduced promising adjunctive strategies. This review critically appraises current and investigational treatment modalities for RA in order to give clinicians an informed up to date picture and to guide them with this difficult to treat population (Figure 1). Emphasis is placed on evaluating the safety profiles, therapeutic efficacy, and the strength of clinical evidence supporting each modality. This review aims to assist clinicians in individualized decision-making for RA management.
No takes yet. Share an insight, caveat, or question.
Angers-Goulet et al. (2025) conducted a review in Refractory angina. Device-based and biologic therapies was evaluated. Current and investigational device-based and biologic therapies offer promising adjunctive strategies for the management of refractory angina in patients who are not candidates for revascularization.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: